DiscoverNewsRamp Health & Wellness PodcastAdvancements in Multisource Mpox Vaccine Supply and Promising Cancer Therapy Results
Advancements in Multisource Mpox Vaccine Supply and Promising Cancer Therapy Results

Advancements in Multisource Mpox Vaccine Supply and Promising Cancer Therapy Results

Update: 2025-10-20
Share

Description

GeoVax Labs, Inc. is emphasizing the need for a multisource Mpox vaccine supply to combat Clade 1 cases in California, while also advancing U.S.-based continuous cell line manufacturing. Meanwhile, Kairos Pharma Ltd. has reported positive interim efficacy data for ENV-105 in men with metastatic castration-resistant prostate cancer, showing promising results in a Phase 2 trial.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Advancements in Multisource Mpox Vaccine Supply and Promising Cancer Therapy Results

Advancements in Multisource Mpox Vaccine Supply and Promising Cancer Therapy Results

NewsRamp